Celldex Therapeutics is a biopharmaceutical company that develops monoclonal and bispecific antibodies targeting mast cell biology and inflammatory pathways to treat diseases where existing treatments are inadequate. The company's primary focus is barzolvolimab, a KIT receptor antagonist in clinical development for multiple mast cell-driven conditions including chronic spontaneous urticaria, cold urticaria, symptomatic dermographism, prurigo nodolaris, and atopic dermatitis, along with CDX-622, a next-generation bispecific antibody designed to neutralize alarmin signaling and deplete mast cells for inflammatory diseases such as asthma. Celldex operates as a pre-revenue development-stage company pursuing a strategy of retaining full economic rights to its therapies or establishing favorable partnerships, with financial success dependent on achieving regulatory approval and commercializing its drug candidates either independently or through collaborators.